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ABSTRACT 
    Intercellular abnormal protein aggregates are a common feature of many 
neurodegenerative diseases. Misfolded proteins are accumulated in neurons and/or glial cells as 
a fibriller, phosphorylated and partially ubiquitinated forms. The distribution and spreading of 
these abnormal proteins in brains of patients are shown to correlate with clinical presentation 
and disease progression. Recent experimental findings support the concept that structurally 
changed abnormal proteins convert normal proteins into abnormal forms and spread into 
neighboring cells in a prion-like manner. This prion-like conversion may account for not only 
the onset but also the progression of neurodegenerative diseases. 
    α-Synuclein (α-syn) is a 140 amino acid protein that is normally located in presynaptic 
nerve terminals. In 1997, missense mutation in the α-syn gene was discovered in families of 
Parkinson’s disease (PD), and subsequent immunohistochemical work with anti-α-syn 
antibodies revealed that α-syn is the major component of Lewy bodies in PD and dementia with 
Lewy bodies (DLB), and also glial cytoplasmic inclusions (GCIs) in multiple system atrophy. 
Purified recombinant α-syn assembles into amyloid-like fibrils that share common properties 
with the fibrils present in pathological human brains in vitro. Preformed α-syn fibrils and brain 
extracts from α-synucleinopathies’ patients can work as seeds to induce seed-dependent 
aggregation in cultured cells. Furthermore, injection of preformed α-syn fibrils into brains of 
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wild-type or transgenic mice overexpressing mutant human α-syn led to development of 
phosphorylated α-syn pathology several months later. However, it has not been fully elucidated 
what structures of α-syn molecules (fibrils or oligomers, soluble or insoluble) are the most 
pathogenic, what sizes of these molecules are the most effective, and what mechanisms underlie 
the cell-to-cell spreading. 
    In this study, I prepared various kinds of α-syn aggregates or intermediates under various 
conditions and tested their prion-like properties in vitro, in cells, and in mouse experimental 
models. I found that only fibril form of α-syn induced seed-dependent aggregation of α-syn in 
cultured cells and in wild-type mouse brains. I also found that sonication of α-syn fibrils 
accelerate accumulation of phosphorylated α-syn, indicating that fragmented β-sheet rich 
fibrous structures of α-syn efficiently induce seed-dependent aggregation and prion-like 
propagation of pathological α-syn in culture cells and wild-type mouse brains. I also 
characterized these α-syn species by transmission electron microscopy observations and 
thioflavin fluorescence assays and found that fibrous structures similar to those observed in 
α-synucleinopathy brains are formed in α-syn fibril-injected mouse brain and that fibrils 
containing sarkosyl-insoluble fractions extracted from injected mice functioned as seeds for 
seed-dependent aggregation of α-syn. These results indicate that fragmented amyloid-like α-syn 
fibrils less than 50 nm in size are the most effective seeds that triggered prion-like conversion. 
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These results may contribute to understand the molecular mechanisms of neurodegenerative 
diseases. These cellular and mouse models of α-syn propagation should be useful for screening 
and evaluation of disease-modifying drugs of α-synucleinopathies. 
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INTRODUCTION 
    Amyloid-like intracellular abnormal protein deposits are the defining feature of many 
neurodegenerative diseases, and the distributions of these pathological proteins are closely 
correlated with disease symptoms and progression (1-3). Recently, it has been experimentally 
demonstrated that these abnormal proteins with amyloid-like cross-β structures have prion-like 
properties and propagate throughout the brains by converting normal proteins into abnormal 
forms. In prion diseases, such as Creutzfeldt-Jakob disease (CJD) and bovine spongiform 
encephalopathy (BSE), abnormal prion protein (PrPSc), which is structurally changed from 
normal prion protein (PrPc) by some kind of triggers, converts PrPC into PrPSc by 
template-dependent multiplication and induces neurodegeneration (Fig. 1) (4). The prion-like 
mechanism similar to that of prion protein may be the main pathogenetic pathway of major 
neurodegenerative disorders, including Alzheimer’s disease (AD), Parkinson’s disease (PD) and 
amyotrophic lateral sclerosis (ALS) (5).  
    α-Synucleinopathies, which include PD, dementia with Lewy bodies (DLB) and multiple 
system atrophy (MSA), are a subset of neurodegenerative diseases characterized by abnormal 
α-syn inclusions in neurons and/or glial cells (6). α-Syn is a 140-amino-acid polypeptide whose 
physiological functions remain to be clarified, but it is localized in presynaptic terminals (7) and 
has roles in various synaptic functions (8-10). Missense mutations and multiplication of the 
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gene linked to the pathogenesis of PD and DLB have been reported in the α-syn gene, SNCA, 
indicating dysfunction and overexpression of α-syn cause PD and DLB (11) (Fig. 2). In 
α-synucleinopathies, aggregated, phosphorylated and partially ubiquitinated α-syn is found as 
Lewy bodies in neuronal cell bodies and as Lewy neurites in dendrites in PD and DLB (12-15) 
(Fig. 3a), while it is found as glial cytoplasmic inclusions (GCIs) in oligodendroglial cells in 
MSA (16) (Fig. 3a). Ultrastructurally, these abnormal α-syn aggregates exhibit filamentous or 
fibrous forms 5~10 nm in width (17).  
    α-Syn is natively unfolded and highly water-soluble (18). However, under physiological 
conditions, purified recombinant human α-syn can polymerize into amyloid-like fibrils that 
morphologically and physicochemically resemble to those in brains of patients (19) (Fig. 4). 
Interestingly, recombinant α-syn with E46K, H50Q or A53T mutation has been shown to form 
fibrils faster than wild-type (WT) (20-23). On the other hand, recombinant α-syn with A30P or 
G51D mutation forms amyloid-like fibrils distinct from those of WT (24,25). Furthermore, 
preformed α-syn fibrils can work as templates to convert normal α-syn into amyloid-like fibrils 
in vitro and in vivo (26-29). Recapitulation of seed-dependent amyloid-like α-syn aggregation, 
with phosphorylation and ubiquitination, was demonstrated by introduction of preformed fibrils 
into cultured cells with transfection reagents (29). Similar seeded aggregation of α-syn was 
observed in primary-cultured neurons, into which extracellular preformed α-syn fibrils were 
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incorporated by endocytosis, and Lewy body-like inclusions were formed (30,31). Prion-like 
conversion of α-syn has also been demonstrated in animal models. Injection of preformed α-syn 
fibrils into brains of wild-type or transgenic mice overexpressing mutant human α-syn led to 
development of phosphorylated α-syn pathology several months later (26,28,32). In these mice, 
injected human α-syn fibrils were degraded in a week and endogenous mouse α-syn was 
accumulated in neurons, which were biochemically indistinguishable from those in DLB. In 
addition, injection of α-syn into different brain regions resulted in injection site-specific 
spreading of α-syn pathology, indicating that pathological α-syn spreads from cell to cell 
through neuronal networks (33). Furthermore, injection of sarkosyl-insoluble fraction 
containing pathological α-syn from synucleinopathies into wild-type or Tg mice overexpressing 
mutant α-syn also caused α-syn pathology and neurodegeneration (28,34,35). Recent studies 
have suggested that there are different kinds of α-syn strains with different biochemical 
properties (36), and injection of different α-syn fibril strains into rat brain caused strain-specific 
α-syn pathologies (37). These results clearly indicate that preformed α-syn fibrils have 
prion-like properties and that pathological α-syn can be transmitted between cells (Fig. 5). 
While preformed fibrils show prion-like activities, it has been suggested that granular or 
ring-like intermediates of fibrils, such as oligomers or pre-fibrils of various sizes, are neurotoxic, 
rather than the fibrils themselves (38-40). However, the oligomers are not well defined, and it 
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remains uncertain whether or not they are actually intermediates in the pathway to fibrils. It is 
also unclear whether α-syn oligomers exist in brains of patients and are involved in disease 
pathogenesis in vivo.  
    As for the prion-like mechanism, it is also unclear what kinds of molecules (fibrils or 
oligomers, soluble or insoluble) are the most pathogenic, what sizes of these molecules are the 
most effective, and what mechanisms underlie the cell-to-cell spreading. Recent studies have 
indicated that structural differences in the pathological proteins may affect the efficiency of 
endocytosis or exocytosis and the seeding activity in cells, as well as transport and toxicity 
(41-43).   
    In this study, I prepared various kinds of α-syn aggregates or intermediates under various 
conditions, and tested their prion-like properties in vitro, in cells, and in mouse experimental 
models. I found that short amyloid-like fibrils with β-sheet structures are the most effective 
triggers of prion-like conversion in all models. These results indicate that α-syn fibrils less than 
50 nm in size can act as prion-like assemblies.  
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MATERIALS and METHODS 
Expression, purification, and preparation of α-syn proteins 
    Human wild-type α-syn and mouse wild-type α-syn in pRK172, a construct containing 
α-syn that lacks cysteine due to mutagenesis of codon 136 (TAC to TAT) as described (44), 
were transformed into Escherichia coli BL21 (DE3). Expression and purification were 
performed as described (45). The protein concentrations of α-syn were determined as described 
(45). Purified recombinant α-syn proteins (5 mg/ml) containing 30 mM Tris-HCl (pH 7.5), 10 
mM DTT and 0.1% sodium azide were incubated at 4, room temperature (20~25), and 
37oC with or without shaking. Incubation with shaking was done with a horizontal shaker 
(TAITEC) at 200 rpm. After incubation for 7 days, the samples were diluted to 2 mg/ml in 
saline. α-Syn samples were analyzed by 12% SDS-PAGE with 2-mercaptoethanol and stained 
with Coomassie Brilliant Blue (CBB). Immunoblotting with polyclonal antibody syn131-140 
(1:2000) directed against a synthetic peptide (residues 131-140) (25,46) was performed as 
described (47). Gel images were recorded with a Gel DocTM EZ Imager (Bio-RAD). 
 
Electron microscopy 
    α-Syn samples were diluted in saline to 0.1 mg/ml, and 0.2 µg aliquots were dropped on 
carbon-coated 300-mesh copper grids (Nissin EM) and incubated for 3 min. After removal of 
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surplus material, the samples were negatively stained for 3 min with a drop of 2% 
phosphotungstic acid and dried. Electron micrograph images were recorded with a JEOL 
JEM-1400 electron microscope (JEOL). 
 
Semiquantitative analysis of the length of sonicated α-syn fibrils 
    α-Syn fibrils were sonicated with a ultrasonic homogenizer (VP-5S, TAITEC) on ice for 0, 
5, 15, 30, 60, and 180 sec. Sonicated fibrils (0.1 mg/ml) were observed at a magnification of 
×10,000 by electron microscopy. Fibril lengths were measured on photographs, and the length 
distribution was calculated. 
 
Thioflavin fluorescence assay 
    The degree of fibrillation was measured in terms of ThS fluorescence intensity, which is 
increased upon binding to amyloid-like fibrils. The samples (10 µl) were incubated with 5 µM 
thioflavin S in 20 mM MOPS buffer (pH 6.8) for 30 min at room temperature. Fluorometry was 
performed using a micro plate reader (440 nm excitation/521 nm emission) as described (48). 
For α-syn seeding assay, amyloid-like fibril formation was monitored in terms of thioflavin T 
fluorescence (excitation 442 nm, emission 485 nm) with a plate reader (VarioskanTM Flash, 
Thermo Scientific). The reaction mixture included 100 µM α-syn monomer and 20 µM 
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thioflavin T in 30 µM Tri-HCl (pH 7.4) in the absence or presence of 5 µM α-syn fibril seeds. 
 
Cell culture, transfection of plasmids and introduction of α-syn proteins into cells 
    Human neuroblastoma SH-SY5Y cells were maintained at 37 in 5% CO2 in Dulbecco’s 
modified Eagle’s medium (DMEM)/F12 medium (Sigma-Aldrich) supplemented with 10% fetal 
calf serum, penicillin-streptomycin glutamine (Gibco), and MEM nonessential amino acids 
solution (Gibco). Cells were cultured to 40-50% confluence in collagen-coated 6-well plates and 
transfected using X-tremeGENE 9 (Roche Life Science) with pcDNA3 or pEGFP encoding 
wild-type human α-syn (1.5 µg) according to the manufacturer’s instructions. After transfection 
of plasmids, cells were incubated for 6-8 h, and α-syn samples (5 µg) were introduced using 
MultiFectam (Promega) according to the manufacturer’s instructions. Transfected cells were 
incubated for 2 days.   
 
Preparation of sarkosyl-insoluble fractions of cultured cells and immunoblotting        
    Transfected SH-SY5Y cells were collected and extracted with 1 ml of 1% sarkosyl in A68 
buffer (10 mM Tris-HCl pH 7.5 containing 10% sucrose, 0.8 M NaCl, 1 mM EGTA). Cell 
extracts were sonicated for 15 sec on ice and collected as total cell lysates. After incubation for 
30 min at 37, cell extracts were ultracentrifuged at 113,000 × g for 20 min at 25. The 
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supernatants were removed and collected as sarkosyl-soluble fractions, then the pellets were 
washed with 30 mM Tris-HCl (pH7.5) and ultracentrifuged as before. The resulting pellets were 
collected as sarkosyl-insoluble fractions, resuspended in 30 mM Tris-HCl (pH7.5) and 
sonicated for 15 sec. Total cell lysates, sarkosyl-insoluble and -soluble fractions were added to 
SDS-sample buffer and heated to 100℃ for 3 min. The protein concentrations of samples were 
determined by PierceTM BCA Protein Assay Kit (Thermo Fisher scientific). Total cell lysates, 
sarkosyl-insoluble and -soluble fractions were separated by 15% SDS-PAGE. Immunoblotting 
with mouse monoclonal antibody PSer129 (1:1000) directed against α-syn phosphorylated at 
Ser129 (13), and polyclonal antibody syn131-140 (1:2000) was performed. Anti-PSer129 
antibody was a kind gift from Dr. Takeshi Iwatsubo. Immunoblotting with monoclonal 
anti-α-tubulin (1:1000, Sigma) was used as a loading control. All experiments were performed 
at least three times. The band intensities of immunoblots were quantified using ImageJ 
software. 
 
Cell viability assay 
    The cytotoxicity of SH-SY5Y cells was assessed by 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using Cell 
Proliferation Kit I (Roche) according to the manufacturer’s instructions.  
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Mice 
    C57BL/6J mice were purchased from CLEA Japan, Inc. All experimental protocols were 
performed according to the Animal Care and Use Committee of the Tokyo Metropolitan 
Institute of Medical Science.  
 
α-Syn inoculation into mice and immunohistochemistry 
    α-Syn samples (10 µg) were injected into striatum (anterior-posterior: 0.2 mm; 
medial-lateral: -2.0 mm; dorsal-ventral: -2.6 mm). Inoculation into mouse brains was performed 
as described (28). At 3 months after inoculation, mice were anesthetized with isoflurane and 
killed by decapitation. Brains were fixed with 10% formalin neutral buffer solution (Wako) and 
sectioned at 50 µm with a Leica VT1200S (Leica). Immunohistochemistry with polyclonal 
antibody 1175 (1:2000) directed against α-syn phosphorylated at Ser129 was performed as 
described (28). For thioflavin-T (ThT) staining, the sections were stained with 0.1 % ThT in 
80 % ethanol for 15 min, then washed with 80 % and 70 % ethanol each for 1 min and distilled 
water twice. α-Syn pathologies were observed and recorded with a BZ-X710 (Keyence). α-Syn 
pathologies were quantified using a BZ-X analyzer (Keyence) and expressed as the percent area 
covered by phosphorylated α-syn deposits of the total area. For preparation of 
sarkosyl-insoluble fractions, brains were snap-frozen on dry ice and stored at -80. 
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Preparation of sarkosyl-insoluble fractions of mouse brains 
    Frozen mouse brains were homogenized in 20 volumes (w/v) of A68 buffer and incubated 
for 30 min at 37, after addition of sarkosyl (final concentration: 2%). Brain homogenates 
were centrifuged at 9,460 × g  for 10 min at 25, then the supernatants were collected and 
ultracentrifuged at 113,000 × g for 20 min at 25. The pellets were washed with saline and 
ultracentrifuged as before. The resulting pellets were collected as sarkosyl-insoluble fractions of 
mouse brains, resuspended in 30 mM Tris-HCl (pH7.5). 
 
Immunoelectron microscopy 
    Sarkosyl-insoluble fractions extracted from injected mice were dropped onto carbon-coated 
nickel grids (Nissin EM). The grids were immunostained with primary antibodies (anti-mouse 
α-syn, syn 131-140, PSer129, 1:200) and secondary antibody conjugated to 10 nm gold 
particles (BBI Solutions, 1:50) as described (49).  Polyclonal anti-mouse α-syn was obtained 
from Cell Signaling Technology. Electron micrograph images were recorded with a JEOL 
JEM-1400 electron microscope (JEOL). 
    Pre-embedding immunoelectron microscopy of α-syn fibril-injected mice was performed 
as follows. Brains were fixed with 4% paraformaldehyde, 0.1% glutaraldehyde (GA) in 
phosphate buffer (PB, pH 7.4) for 1 h and thin-sectioned. The sections were treated with 0.5% 
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H202 in methanol for 30 min and 0.05% TritonXTM-100 in PBS, blocked with 10% calf serum in 
PBS and incubated with the primary antibody (1175, 1:200). After extensive washing, the 
sections were incubated with secondary antibody conjugated to nanogold particles (1:50). 
Immunostained sections were fixed with 2% GA in PB at 4 oC overnight. The nanogold particles 
were enhanced with GOLDENHANCE EM Formulation (Nanoprobes), and the sections were 
dehydrated in graded ethanol solutions (50%, 70%, 90%, 100%), infiltrated with propylene 
oxide (PO) and polymerized in resin (Quetol-812; Nisshin EM) at 60 oC for 48 h. The 
polymerized resin were ultra-thin-sectioned at 80 nm using Ultracut UCT (Leica) and the 
sections were mounted on copper grids and stained for 15 min with 2% uranyl acetate. Electron 
micrograph images were recorded with a JEOL JEM-1400Plus electron microscope (JEOL). 
 
Gel filtration chromatography  
    α-Syn samples were centrifuged at 20,000 × g for 10 min at 25. The supernatants and 
monomeric α-syn were analyzed by size-exclusion HPLC on a Superdex 200 Increase 5/150 GL 
(GE Life Sciences) equilibrated with 10 mM Tris-HCl pH 7.5, 0.15 M NaCl. Protein elution 
was monitored at 215 nm. Separated fractions were analyzed by 12% SDS-PAGE and stained 
with Coomassie Brilliant Blue (CBB).  
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Live cell imaging 
    α-Syn fibrils formed by shaking at 37 were labeled with an Alexa Fluor 546 Protein 
Labeling Kit (Invitrogen) according to the manufacturer’s instructions. Fluorescence-labeled 
α-syn fibrils with or without sonication (180 sec) were introduced into SH-SY5Y cells 
transfected with pEGFP wild-type human α-syn (1.5 µg) in 6-well plates. After introduction of 
α-syn fibrils, live-cell imaging was performed using a BZ-X710 (Keyence) with monitoring at 
multiple sample points every 15 min for 37 h. Cells were maintained at 37 and 5% CO2 using 
an Incubation System For Microscopes (TOKAI HIT) during observation. Images were 
analyzed using a BZ-X analyzer (Keyence). 
 
Statistical analysis 
    The unpaired, two-tailed Student’s test was used for all analyses in figures. A P value < 
0.05 was regarded as statistically significant. 
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RESULTS 
Fibril form of α-syn acts as seeds for prion-like conversion 
    To investigate what kinds of α-syn species are most effective for prion-like conversion of 
normal α-syn into an abnormal form, I prepared several kinds of α-syn aggregates or 
intermediates under various conditions, and examined their seeding ability. Purified 
recombinant human α-syn was incubated under the following conditions: standing at 4, room 
temperature (20~25), and 37 or shaking at 37. Electron microscopy (EM) analysis after 
incubation for 7 days revealed that α-syn shaken at 37 formed fibrous structures (Fig. 6); on 
the other hand, oligomer-like structures were observed in the samples at room temperature and 
37 without shaking. Coomassie Brilliant Blue (CBB) staining of SDS PAGE gels and 
immunoblotting of these α-syn samples showed that α-syn shaken at 37  contained 
SDS-stable dimers and high-molecular-weight polymers in addition to monomers (Fig. 7a). 
Thioflavin S (ThS) fluorescence intensity measurements of these samples indicated that the 
fibril form of α-syn after shaking at 37  contained β-sheet structures, while the other 
oligomer-like structures did not (Fig. 7b). To examine the abilities of these α-syn forms to 
convert normal α-syn into abnormal form, I introduced them as seeds in the presence of the 
transfection reagent into SH-SH5Y cells ectopically expressing human α-syn, and investigated 
the seeded aggregations of α-syn in these cells as previously reported (29). Sarkosyl-insoluble 
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phosphorylated α-syn similar to those in patients with α-synucleopathies (13) was detected in 
cells into which the fibril form of α-syn, but not monomeric α-syn or the other samples, had 
been introduced (Fig. 8). I also conducted experiments using cells not overexpressing human 
α-syn and cells into which α-syn samples had been introduced in the absence of the transfection 
reagent, and found similar propensities in both cases (Fig. 9). These results suggest that fibril 
form of α-syn, but not the intermediates, is responsible for seeded aggregation. In the following 
SH-SY5Y cell-based experiments, I used the method corresponding to that used for Fig. 8 to 
introduce α-syn samples, as this appeared most effective for seeded aggregation of α-syn. I also 
tested the cytotoxity of SH-SY5Y cells at 2 days after introduction of α-syn samples by means 
of the widely used MTT assay (Fig. 10). A significant reduction of MTT was detected in cells 
with intracellular accumulation of phosphorylated α-syn aggregates. To confirm good 
correspondence between the cellular model and mouse model, the same samples were injected 
into the striatum of C57BL/6J mice. As in the cellular model, accumulation of phosphorylated 
α-syn aggregates was observed at 3 months after inoculation in mice inoculated with fibrils 
formed by shaking at 37, whereas no such pathology was observed in mice inoculated with 
other samples (Fig. 11). These results suggest that only α-syn fibrils containing β-sheet 
structures work as seeds for prion-like conversion of normal α-syn and cause aggregation of 
α-syn in both cultured cells and mouse brain. 
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Seeding activities of α-syn fractions obtained by centrifugation 
    To further investigate what kind of α-syn fibrils causes seed-dependent aggregation, the 
α-syn fibrils after shaking at 37  were fractionated into supernatant and pellet by 
centrifugation and the seed-dependent aggregation abilities of the fractions were examined. 
α-Syn fibrils formed by shaking at 37 for 7 days were sonicated or suspended by pipetting, 
and then fractionated by centrifugation at 20,000 x g for 10 min. ThS fluorescence intensity 
measurements showed that the supernatant of the sonicated samples contained many 
amyloid-like fibrils, whereas suspended (unsonicated) samples contained less fibrils than the 
pellet (Fig. 12a). EM observation confirmed that fibrillar structures were present in the 
supernatants of both samples (Fig. 12b) and that more fragmented fibrils were found in the 
supernatant of the sonicated sample. To test the ability of these fractions to induce 
seed-dependent aggregation of α-syn, the fractions were introduced into SH-SY5Y cells and 
accumulation of sarkosyl-insoluble phosphorylated α-syn was examined (Fig. 13a). When the 
fractions from fibrils without sonication were introduced into cells, an increased level of 
phosphorylated α-syn was observed compared to the case of cells treated with monomeric 
α-syn, and little difference was detected among the fractions (Fig. 13b). In contrast, a dramatic 
increase of phosphorylated α-syn was detected in the case of sonicated fibrils (total and 
supernatant), whereas only a small increase was observed after introduction of the pellet (Fig. 
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13b), strongly suggesting that short, fragmented fibrils formed by sonication, which were 
ThS-positive, efficiently acted as seeds. Next, to confirm whether the supernatant fraction also 
causes abnormal accumulation of α-syn in vivo, it was injected into mouse brain and 
pathological changes of α-syn were evaluated 3 months later by immunohistochemistry with a 
phospho-α-syn antibody (Fig. 14). Supernatant of sonicated α-syn fibrils also induced 
accumulation of phosphorylated α-syn in mouse brain. These results indicated that fragmented 
α-syn fibrils in the centrifugal supernatant are the major cause of seed-dependent aggregation of 
α-syn in both cultured cells and mouse brain, and are the most effective seeds among the forms 
of α-syn examined.  
 
Seeding activity of α-syn fibrils fragmented by sonication 
    To further investigate the effect of sonication and to examine the relationship between 
fibril size and seeding activity, I prepared different sizes of fibrils by sonication and tested their 
seeding activity. α-Syn fibrils formed by shaking at 37 were sonicated for various time 
periods and the resulted fibrils were observed with an EM (Fig. 15a). Without sonication, many 
elongated fibrils were seen, but as the time of sonication was increased, the α-syn fibrils 
became shorter and more fragmented. Semi-quantitative analysis of fibril lengths showed that 
short fibrils of less than 50 nm in length constituted approximately 80 % of fibrils that had been 
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sonicated for 180 sec (Fig. 15b). However, the fluorescence intensity of ThS did not change, 
indicating that β-sheet content and ThS accessibility were unaffected by the fragmentation (Fig. 
16a). Next, I examined whether fragmentation affected the seeding ability and prion-like 
properties in vitro and in vivo. First, to test whether these fragmented fibrils can act as seeds for 
prion-like conversion of normal α-syn monomer into fibrils in vitro, I incubated monomeric 
α-syn with a small amount of these fibrils as seeds and measured the kinetics of ThS 
fluorescence (Fig. 16b). Fragmented fibrils accelerated the polymerization of α-syn monomers, 
while the fibrils without sonication showed little effect. Moreover, the acceleration increased in 
direct proportion to sonication time, suggesting that shorter fibrils are more effective for 
seed-dependent aggregation. I also examined the seeding effects of diluted sonicated fibrils (180 
sec) and compared them with that of unsonicated fibrils (Fig. 16c). The kinetics of ThT seeded 
with unsonicated fibrils were similar to these after seeding with 1/40 or 1/60 diluted sonicated 
fibrils, indicating that the seeding activity was dependent on the number of fibrils ends. Next, 
these fragmented fibrils were introduced into SH-SY5Y cells, and accumulation of 
sarkosyl-insoluble phosphorylated α-syn was examined (Fig. 17a). As with seeding assay in 
vitro, accumulation of sarkosyl-insoluble α-syn increased significantly in direct proportion to 
the sonication time of the fibrils (Fig. 17b). As regards cytotoxity, there was a significant 
correlation between increased amounts of phosphorylated α-syn and MTT reduction (Fig. 18). 
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To examine the effect of fragmentation on incorporation into cells, the fibrils were labeled with 
Alexa 567 and introduced into cells, and imaging of the live cells was performed (Fig. 19). 
Incorporation of fragmented fibrils into cells was frequently observed, whereas unsonicated 
fibrils were clumped and hardly incorporated. 
Furthermore, I examined whether accumulation of phosphorylated α-syn was also increased in 
mice inoculated with α-syn fibrils. These sonicated α-syn fibrils were injected into mouse brain 
and pathological changes were examined 3 months later by means of immunohistochemistry of 
phosphorylated α-syn. Compared with inoculation of untreated α-syn fibrils (Fig. 11), 
fragmented α-syn fibrils (such as fibrils sonicated for 180 sec) caused more extensive 
seed-dependent aggregation and wider-ranging propagation of phosphorylated α-syn, as I had 
observed in cultured cells (Fig. 20, Fig. 21a). Also, thioflavin-T positive aggregates were 
observed in fibril-injected mouse brains (Fig. 21b). Phosphorylated α-syn deposits resembling 
Lewy bodies and Lewy neurites were observed in striatum, amygdala, substantia nigra, 
somatosensory cortex, cingulate cortex and corpus callosum, as previously reported (33) (Fig. 
21c). Thus, sonication of α-syn fibrils had a significant effect on accumulation of 
phosphorylated α-syn in mouse brain. As regards the propagation patterns of α-syn 
accumulation, there was little difference between samples sonicated for 60 and 180 sec, while 
phospho-syn pathology induced by the sample sonicated for 15 sec was less extensive than that 
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induced by the sample sonicated for 180 sec. These results showed that more extensively 
fragmented α-syn fibrils also have a higher ability to cause seed-dependent aggregation of 
α-syn in mouse brain. 
It is possible that more extensive fragmentation of α-syn fibrils allows them to be incorporated 
into cells more efficiently, resulting in increased seeding activity for prion-like propagation due 
to greater acceleration of α-syn polymerization. 
 
Isolation of α-syn that causes seed-dependent aggregation by gel filtration 
chromatography 
    To characterize the fragmented α-syn fibrils and their effects on seed-dependent 
aggregation of α-syn, sonicated α-syn samples were fractionated by gel filtration 
chromatography and the prion-like properties of the fractions were examined. α-Syn fibrils with 
or without sonication and monomer were fractionated based on molecular weight by means of 
gel filtration chromatography (Fig. 22a). One broad single peak with a retention time of 4 
minutes (fraction 5) was detected for monomeric α-syn. A single peak with a retention time of 2 
minutes (fraction 2) at the position of the void volume and a small peak at 5 minutes were 
detected when α-syn fibrils sonicated for 180 sec were fractionated, whereas only a small peak 
at 5 minutes was detected when unsonicated α-syn fibrils was fractionated (full-length fibrils 
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seemed to be retained in the pre-column filter). EM analyses of these fractions showed that 
short fibrils were recovered in fraction 2, while no such fibrils were detected in fraction 5 (Fig. 
22b). Furthermore, fragmented α-syn fibrils sonicated for various times were fractionated, and 
samples of fractions 2 and 5 were analyzed by CBB staining of SDS-PAGE gels and ThS 
fluorescence assays (Fig. 23). A large amount of α-syn protein was recovered in fraction 5 from 
the monomeric α-syn sample, but little α-syn was detected from α-syn fibrils. ThS fluorescence 
intensity in fraction 5 from all samples was not increased, indicating that monomeric α-syn 
protein was eluted in fraction 5. The amount of α-syn protein in fraction 2 increased in 
proportion to the sonication time, and corresponded to the increase of ThS fluorescence 
intensity. These results indicated that short fibrils with β-sheet-rich structure were present in 
fraction 2. No peak was detected from the sample of α-syn fibrils without sonication, suggesting 
that long fibrils were not eluted from the column under the conditions used. Next, samples from 
fraction 2 were introduced into SH-SY5Y cells, and seed-dependent aggregation of α-syn was 
examined. Introduction of fraction 2 eluted from α-syn fibrils sonicated for 180 sec resulted in 
the highest accumulation of sarkosyl-insoluble phosphorylated α-syn (Fig. 24a). In addition, 
accumulation of phosphorylated α-syn was highly correlated with amount of α-syn fibrils 
recovered in fraction 2 (Fig. 24b). These results showed that short α-syn fibrils in the void 
volume fraction had potent ability to cause seed-dependent aggregation of α-syn. 
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Isolation of sarkosyl-insoluble fraction from α-syn-injected mice 
    To examine whether fibril forms of α-syn, such as those observed in the brains of 
α-synucleinopathies, exist in mouse brain injected with α-syn fibrils, I performed 
immunoelectron microscopy and isolation of pathological α-syn from mouse brain injected with 
mouse or human α-syn fibrils. Immuno-EM observation at 23 months after inoculation revealed 
that numerous phosphorylated α-syn (pS129)-positive fibrous structures had accumulated 
around the nuclei in neuronal cells of wild-type mouse brain injected with mouse α-syn fibrils 
(Fig. 25). Next, sarkosyl-insoluble fraction was prepared from mouse brain injected with 
monomeric human α-syn or human α-syn fibrils at 18 months after inoculation. Immuno-EM 
observation demonstrated that fibrous α-syn structures were present only in the 
sarkosyl-insoluble fraction from α-syn fibril-injected mouse brain (Fig. 26a). The fibrils were 
~10 nm in diameter, which is similar to those found in brain of α-synucleinopathy patients (17). 
These fibrous structures were positively stained with antibodies to syn131-140, phosphorylated 
α-syn and also an antibody specific for mouse α-syn, indicating that endogenous mouse α-syn 
is accumulated as fibrous forms. Immunoblot analysis indicated that accumulated endogenous 
mouse α-syn was phosphorylated in fibril-injected mice, but not in monomer-injected mice or 
fibrils prepared in vitro (Fig. 26b). To investigate whether these sarkosyl-insoluble fractions 
extracted from injected mice can induce seed-dependent aggregation of α-syn, they were 
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introduced into SH-SY5Y cells and accumulation of sarkosyl-insoluble phosphorylated α-syn 
was examined (Fig. 27a). The introduction of sarkosyl-insoluble fractions extracted α-syn from 
fibril-injected mice resulted in accumulation of phosphorylated α-syn, whereas the same 
fraction from monomer-injected mice did not. Furthermore, sonication of the introduced 
sarkosyl-insoluble fractions increased the accumulation of phosphorylated α-syn (Fig. 27b). 
These results demonstrate that fibrous structures similar to those observed in α-synucleinopathy 
patient’s brains were formed in α-syn fibril-injected mouse brain, and fibrils in 
sarkosyl-insoluble fractions extracted from injected mice functioned as seeds for 
seed-dependent aggregation of α-syn. 
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DISCUSSION 
    Many in vitro and in vivo experimental models have demonstrated that the intracellular 
abnormal proteins characteristic of major neurodegenerative diseases, such as α-syn in PD, tau 
in AD and TDP-43 in ALS/frontotemporal lobar degeneration (FTLD) have prion-like 
properties, and that the intracellular conversion of normal proteins into abnormal forms and 
cell-to-cell spreading of the abnormal forms can occur. To understand the relationships between 
the phenomena in experimental models and those in brains of patients, I investigated the 
prion-like properties (transmissibility) of various α-syn species in vitro, in cells and in animal 
models as previously reported (28,29). The findings indicate that short α-syn fibrils with lengths 
of less than 50 nm are the most effective molecular triggers of formation and spreading of 
abnormal α-syn, by acting as seeds for prion-like conversion in cultured cells and mouse brains. 
In vitro experiment, conversion of normal soluble α-syn into amyloid-like fibrils was 
accelerated by addition of small amounts of preformed α-syn fibrils, and the acceleration was 
increased in proportion to the sonication time of fibrils (Fig. 16b), suggesting that fragmentation 
of the fibrils is important for the prion-like conversion. Indeed, the similarity of kinetics of fibril 
α-syn formation seeded with unsonicated fibrils and 1/40 or 1/60 diluted sonicated fibrils 
implies that the seeding activity was dependent on the number of fibrils ends and that the 
number of fibrils was increased 40 to 60 times after sonication for 180 sec (Fig. 16c). This 
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seems consistent with the observed lengths of fibrils (Fig. 15b). In cultured cells, introduction of 
fragmented α-syn fibrils also promoted seed-dependent aggregation (Fig. 17). This finding is 
consistent with a previous report showing that short fibrils induce seeded aggregation of 
endogenous α-syn in cultured cells without overexpression (50). I also found that increased 
cytotoxicity was correlated with increased accumulation of intracellular phosphorylated α-syn 
aggregates (Fig. 18), but the observed cytotoxicities were comparatively low. This low 
propensity for cytotoxicity may be consistent with the extremely long silent period from the 
accumulation of α-syn aggregates until neuronal loss in patient’s brains. In mice, fragmented 
α-syn fibrils in which more than 80 % of fragments were less than 50 nm in size were the most 
efficient for prion-like propagation (Fig. 20). Although exogenously injected α-syn fibrils were 
degraded within a week (28), fragmented fibrils may continue to act on endogenous mouse 
α-syn until they are digested, generating widespread pathology. Therefore, control of 
propagation may require a focus on newly generated seeds.   
    Lewy bodies and Lewy neurites observed in patients are composed of filamentous α-syn 
200-600 nm in length and 5-10 nm in width (17). Similarly, immuno-EM of α-syn 
fibril-injected wild-type mouse brain in this study revealed numerous comparatively long 
fibrous structures with approximately ~10 nm width around nuclei (Fig. 25). The accumulations 
of fibrous structures were also confirmed by immuno-EM of sarkosyl-insoluble fraction of 
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mouse brains with antibodies specific for mouse α-syn and phosphorylated α-syn (Fig. 26a). 
These results indicated that recombinant α-syn fibrils acted as a pathogenic factor to convert 
endogenous mouse α-syn into amyloid-like fibrils. Furthermore, sonication of 
sarkosyl-insoluble fractions containing these fibrils resulted in enhancement of the seeding 
activity in cultured cells (Fig. 27), raising the possibility that the breaking of once-elongated 
fibrils into short fragments in vivo enhances the prion-like activities of seeds, promoting 
cell-to-cell spreading. This is consistent with a report that fragmented amyloid-like fibrils have 
distinct properties from long fibrils (42), indicating that fragmentation of fibrous structures may 
be a critical first step in transmission. 
Many studies on prion-like proteins in experimental models have suggested that sonication of 
amyloid or amyloid-like fibrils significantly enhances seeding activity. Fragmented amyloid 
fibrils induced cytotoxicity in vitro (42) and small soluble Aβ seeds found in brain extracts 
isolated from APP transgenic mice caused intracerebral propagation in vivo (51). On the other 
hand, Wu et al. reported that small tau aggregates were internalized in neuronal cells (41), and 
Jackson and Kerridge et al. demonstrated that short fibrous tau assemblies with an average 
length of 179 nm isolated from P301S tau mice induced seed-dependent propagation in vivo 
(52). These findings are broadly consistent with this finding that fibrous α-syn seeds less than 
50 nm in length (approximately 40 % of them were only 25 nm) have the highest seeding 
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activity in the prion-like propagation. It is plausible that smaller structures would be more easily 
incorporated into cells by endocytosis. There is evidence that α-syn fibrous structures interact 
with cellular membranes, can move between cells, and are secreted from axons (53,54). 
Additionally, Pieri et al. reported that α-syn fibrils are more cytotoxic than oligomeric species 
(55). The presence of short fibrous structures in the supernatants after ultracentrifugation (25) or 
high-speed centrifugation (Fig. 12b) supports the possibility that oligomers (considered as 
intermediates of fibrils) may include quite short fibrils. In prion proteins, nonfibrillar small 
particles showed the most infectivity and sonication enhance their transmissibility (56). Taking 
these results together, it seems that there are common features in the cell-to-cell spreading and 
transmission of pathogenic species of various prions and prion-like proteins. 
    In general, sonicated recombinant α-syn fibrils are used to induce cell-to-cell spreading in 
cellular and animal experimental models (32,57), and it can be difficult to establish the 
relevance of such studies to the prion-like propagation seen in patients with α-synucleinopathies. 
However, advantages of that approach are that well-characterized short fibrils can be prepared, 
and inoculation samples are not contaminated with other factors that might influence 
propagation. However, there are clearly issues over interpretation, because the data indicate that 
differences of preparation procedures, including degree of sonication of preformed α-syn fibrils, 
can greatly influence the results. It is also noteworthy that familial PD α-syn mutant A30P 
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fibrils are more fragile than WT α-syn fibrils (25).  
    In this work, I investigated the seeding activity of various α-syn species in various 
experimental models of prion-like propagation and found that fragmented β-sheet-rich fibrous 
α-syn species (50 nm or less in length) were the most effective in inducing seed-dependent 
aggregation of α-syn in all the experimental models. Further study is needed to elucidate the 
precise mechanisms underlying the prion-like propagation. 
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FIGURES LEGENDS 
    Fig. 1. The seeding model of prion 
Misfolded forms of prion proteins (PrPSc) are the cause of prion diseases. Abnormal prions 
have the ability to self-propagate by changing normal prion protein (PrPC) into abnormal form, 
resulting in neurologic dysfunction. 
 
Fig. 2. Schematic representation of human α-syn 
 The structure of α-syn consists of three regions: residues 1-60 (blue box), which is an 
amphipathic region, residues 61-95 (orange box), which contains a hydrophobic and 
non-β amyloid component (NAC), and residues 96-140 (red box), which is highly acidic 
region and present several negative charges. Purple boxes show 11 amino acid imperfect 
repeats partially conserved KTKEGV motifs. The six missense mutations located in these 
regions are indicated in red. The residue serine 129 is phosphorylated in α-synucleinopathies 
(green round).  
 
Fig. 3. Brains of DLB and MSA cases contain pathogenic α-syn. 
 Lewy bodies (arrows) and Lewy neuritis (arrowheads) detected by anti-phosphorylated α-syn 
PSer129 antibody in DLB (a). Glial cytoplasmic inclusions detected by anti-phosphorylated 
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α-syn PSer129 antibody in MSA (b). 
 
Fig. 4. Fibrous structures of DLB patients’ brain and recombinant α-syn aggregates 
formed in vitro 
Straight α-syn fibrils in sarkosyl-insoluble fraction from DLB patients’ brain show positive 
with anti-phosphorylated α-syn PSer129 antibody (a). Abnormal fibrils are 
thioflavin-S-positive and show amyloid-like properties with cross-β structures. Purified 
recombinant α-syn assembles into amyloid-like fibrils in vitro (b). These fibrils share 
common morphological, ultrastructural, and biochemical properties with the fibrils present in 
pathological human brains. The scale bar represents 50 nm. 
 
Fig. 5. Schematic representation of a prion-like mechanism in neurodegenerative 
diseases 
When prion-like protein aggregates are formed for some reason, it converts normal proteins 
into an abnormal form in a nucleation-dependent manner. Then, abnormal protein aggregates 
self-propagate and spread into neighboring healthy cells in succession. 
 
 - 33 - 
Fig. 6. Negative staining electron microscopy of α-syn samples formed at various 
conditions  
Electron microscopy of α-syn samples subjected to the following conditions: shaking at 37 oC, 
standing at 4 oC, RT and 37 oC for 7 days. Negatively stained fibrils and oligomer-like 
structures were observed. The scale bar represents 200 nm. 
 
Fig. 7 . Biochemical analysis of α-syn samples formed at various conditions  
Monomer α-syn and α-syn samples (0.5 µg of protein of each) were analyzed by Coomassie 
Brilliant Blue (CBB) staining and immunoblotting with anti-syn 131-140 antibody (a). ThS 
fluorescence of monomer α-syn and α-syn samples (b). The results are expressed as    
means ± SEM. (n=3). A.U., arbitrary unit. 
 
Fig. 8. Immunoblot analysis of cells treated with α-syn samples formed at various 
conditions  
α-Syn samples (5 µg) were introduced into SH-SY5Y cells overexpressing human α-syn in the 
presence of the transfection reagent. Immunoblot analysis of sarkosyl-insoluble fractions (ppt), 
total cell lysates (total lysate) and sarkosyl-soluble fractions (sup) extracted from cells 
transfected with mock, α-syn monomer, 37 oC shake, 37 oC stand, RT stand and 4 oC stand are 
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shown (a). Phosphorylated α-syn was detected with anti-phosphorylated α-syn PSer129 
antibody. α-Syn was detected with anti-syn 131-140 antibody. Tubulin-α was used as the 
loading control. Quantification of PSer129-positive sarkosyl-insoluble fractions shown in Fig.8 
(a) (b). The results are expressed as means ± SEM. (n=3). A.U., arbitrary unit. 
 
Fig. 9. The effect of transfection methods on seed-dependent aggregation in cultured cells 
α-Syn samples (5 µg) were introduced into SH-SY5Y cells without overexpressing human 
α-syn in the presence of the transfection reagent. Also, α-Syn samples (5 µg) were introduced 
into SH-SY5Y cells with overexpressing human α-syn in the absence of the transfection reagent. 
Immunoblot analysis of sarkosyl-insoluble fractions and sarkosyl-soluble fractions extracted 
from cells without overexpressing human α-syn (a) and introduced α-syn samples in the 
absence of the transfection reagent (b). Phosphorylated α-syn was detected with 
anti-phosphorylated α-syn PSer129 antibody. α-Syn was detected with anti-syn 131-140 
antibody. Tubulin-α was used as the loading control. 
 
Fig. 10. Cytotoxicities of cells treated with various α-syn samples 
Cell viability of SH-SY5Y cells introduced with α-syn samples shown in Fig. 8 (a). The 
cytotoxicity was assessed by MTT assay. The results are expressed as means ± SEM. (n=6). *P 
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< 0.05, **P <0.01 by Student’s t-test against the value of control (mock).  
 
Fig. 11. Immunohistochemical analysis of mouse brains injected with α-syn samples 
formed at various conditions  
Distribution of phosphorylated α-syn pathology in mouse brain. WT mouse brain was 
injected with α-syn samples (10 µg) into striatum and observed 3 months later (n=7 for 37 oC 
shake, n=5 for 37 oC stand, n=3 for RT stand, n=2 for 4 oC stand). Phosphorylated α-syn 
pathology was evaluated by immunohistochemistry with PSer129 antibody 1175. Typical 
images of brain injected with 37 oC shake (left) and 37 oC stand (right) are shown (upper 
images). Schematic diagrams of phosphorylated α-syn pathology at the level of 0.62 mm 
from bregma are shown (lower panels). Red dots indicate phosphorylated α-syn pathology. 
The scale bar represents 100 µm. 
 
Fig. 12. Amyloid-like properties of α-syn fractions obtained by centrifugation  
Thioflavin S fluorescence of α-syn fibrils shaken at 37 oC for 7 days with or without sonication. 
Total α-syn (total) was fractionated into supernatant (sup) and pellet (ppt) by centrifugation (a). 
The results are expressed as means ± SEM. (n=3). A.U., arbitrary unit. Electron microscopy of 
α-syn fibrils in supernatant after centrifugation without sonication or with sonication (b). The 
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scale bar represents 200 nm.  
 
Fig. 13. Immunoblot analysis of cells treated with α-syn fractions obtained by 
centrifugation 
α-Syn samples (2.5µl) were introduced into SH-SY5Y cells overexpressing human. α-syn 
Immunoblot analysis of sarkosyl-insoluble fractions (ppt), total cell lysates (total lysate) and 
sarkosyl-soluble fractions (sup) extracted from cells transfected with mock, α-syn monomer, 
α-syn samples without sonication, total α-syn, supernatant, pellet and α-syn samples with 
sonication, total α-syn, supernatant, pellet are shown (a). Phosphorylated α-syn was detected 
with anti-phosphorylated α-syn PSer129 antibody. α-Syn was detected with anti-syn 131-140 
antibody. Tubulin-α was used as the loading control. Quantification of PSer129-positive 
sarkosyl-insoluble fractions shown in Fig. 13 (a) (b). The results are expressed as means ± SEM. 
(n=3). *P < 0.05, **P <0.01 by Student’s t-test against the value of monomer. A.U., arbitrary 
unit. 
 
Fig. 14. Immunohistochemical analysis of mouse brains injected with the α-syn fraction 
obtained by centrifugation  
Distribution of phosphorylated α-syn pathology in mouse brain. WT mouse brain was injected 
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with supernatant after centrifugation of sonicated α-syn fibrils (10 µl) into striatum and 
observed 3 months later (n=2). Phosphorylated α-syn pathology was evaluated by 
immunohistochemistry with PSer129 antibody 1175. Typical image of brain (left) and a 
schematic diagram of phosphorylated α-syn pathology (right) at the level of 0.62 mm from the 
bregma are shown. Red dots indicate phosphorylated α-syn pathology. The scale bar represents 
100 µm. 
 
Fig. 15. Fibrous structures and fibril lengths of α-syn fragmented by sonication 
Electron microscopy of α-syn fibrils after sonication for 0 sec, 5 sec, 15 sec, 30 sec, 60 sec, and 
180 sec (a). The scale bar represents 200 nm. Semiquantitative analysis of the length of  
sonicated α-syn fibrils (b). 
 
Fig. 16. In vitro seeding activity of α-syn fragmented by sonication 
Thioflavin S fluorescence of monomer α-syn and sonicated α-syn fibrils (a). The results are 
expressed as means ± SEM. (n=3). ThT fluorescence of monomer α-syn after addition of 
sonicated α-syn fibrils (b). ThT fluorescence of monomer α-syn after addition of α-syn fibrils 
without sonication or a various dilution series of sonicated α-syn fibrils (180 sec) (c). A.U., 
arbitrary unit. 
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Fig. 17. Immunoblot analysis of cells treated with α-syn fragmented by sonication 
α-Syn samples (5 µg) were introduced into SH-SY5Y cells overexpressing human α-syn. 
Immunoblot analysis of sarkosyl-insoluble fractions (ppt), total cell lysates (total lysate) and 
sarkosyl-soluble fractions (sup) extracted from cells transfected with mock, α-syn monomer, 
α-syn fibrils after sonication for 0 sec, 15 sec, 60 sec and 180 sec (a). Phosphorylated α-syn 
was detected with anti-phosphorylated α-syn PSer129 antibody. α-Syn was detected with 
anti-syn 131-140 antibody. Tubulin-α was used as the loading control. Quantification of 
PSer129-positive sarkosyl-insoluble fractions shown in Fig.17 (a) (b). The results are expressed 
as means ± SEM. (n=3). A.U., arbitrary unit. 
 
Fig. 18. Cytotoxicities of cells treated with α-syn fragmented by sonication 
Cell viability of SH-SY5Y cells introduced with α-syn samples shown in Fig. 17 (a). The 
cytotoxicity was assessed by MTT assay. The results are expressed as means ± SEM. (n=6). ns, 
not sighnificant, *P < 0.05, **P < 0.01, ***P < 0.001 by Student’s t-test against the value of 0 
sec. 
 
Fig. 19. Live cell imaging of SH-SY5Y cells after introduction of α-syn fibrils 
Fluorescence-labeled α-syn fibrils (4 µg) without sonication (a) or after sonication for 180 sec 
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(b) were introduced into SH-SY5Y cells overexpressing GFP-tagged human  α-syn. 
Incorporation of α-syn fibrils into cells was observed by time-lapse microscopy. Monitoring 
was initiated after introduction of α-syn fibrils. The scale bar represents 50 µm.  
 
Fig. 20. Immunohistochemical analysis of mouse brains injected with α-syn fragmented by 
sonication  
Distribution of phosphorylated α-syn pathology in brain of mice observed 3 months after 
injection of α-syn samples (10 µg) into striatum (Str). Phosphorylated α-syn pathology was 
evaluated by immunohistochemistry with PSer129 antibody 1175. Typical images of brain 
injected with α-syn fibrils sonicated for 0 sec (n=7, left, upper image), 15 sec (n=3, right, upper 
image), 60 sec (n=3, left, lower image) and 180 sec (n=3, right, lower image) are shown. 
Schematic diagrams of phosphorylated α-syn pathology at the level of 0.62 mm from bregma 
are shown (left, next to images). Red dots indicate phosphorylated α-syn pathology. The scale 
bar represents 100 µm.  
 
Fig. 21. In vivo seeding activity of α-syn fragmented by sonication 
Quantification of α-syn pathology in mice injected with α-syn fibrils into Str shown in Fig.19  
(a). The results are expressed as means ± SEM. (n=3). *P < 0.05 by Student’s t-test against the 
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value of 0 sec. ThT staining in Str of mice injected with α-syn fibrils sonicated for 180 sec into 
Str (b). The scale bar represents 25 µm. Widespread phosphorylated α-syn pathology in mice 
injected with α-syn fibrils sonicated for 180 sec into Str (c). The scale bar represents 20 µm. 
 
Fig. 22. Isolation of various α-syn species by means of gel filtration chromatography 
Separation of monomeric α-syn and α-syn fibrils with or without sonication by gel filtration 
chromatography (a). Fractions were collected every 0.5 minutes. Electron microscopy of 
fraction 5 isolated by gel filtration chromatography from monomer α-syn and fraction 2 isolated 
from α-syn fibrils after sonication for 180 sec (b). The scale bar represents 200 nm. 
 
Fig. 23. Biochemical analysis of fractions obtained by gel filtration chromatography 
SDS-PAGE and ThS fluorescence of fraction 2 (a) and fraction 5 (b) isolated by gel filtration 
chromatography from monomer α-syn, and α-syn fibrils after sonication for 0 sec, 5 sec, 15 sec, 
30 sec, 60 sec and 180 sec. A.U., arbitrary unit. 
 
Fig. 24. Immunoblot analysis of cells treated with fractions obtained by gel filtration 
chromatography 
Fraction 2 (10 µl) was introduced into SH-SY5Y cells overexpressing human α-syn. 
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Immunoblot analysis of sarkosyl-insoluble fractions (ppt) and sarkosyl-soluble fractions (sup)  
extracted from cells transfected with fraction 2 isolated by gel filtration chromatography from 
α-syn fibrils sonicated for 0 sec, 5 sec, 15 sec, 30 sec, 60 sec and 180 sec (a). Phosphorylated 
α-syn was detected with anti-phosphorylated α-syn PSer129 antibody. α-Syn was detected with 
anti-syn 131-140 antibody. Tubulin-α was used as the loading control. Quantification of 
PSer129-positive sarkosyl-insoluble fractions shown in Fig.23 (a) (b). The results are expressed 
as means ± SEM. (n=3). *P < 0.05 by Student’s t-test against the value of 0 sec. A.U., arbitrary 
unit. 
 
Fig. 25. Immunoelectron microscopy of α-syn fibril-injected mice  
Immunoelectron microscopy of anti-phosphorylated α-syn (1175)-positive fibrous structures 
(arrows) in brain of a mouse injected with α-syn fibrils, detected with gold particles. The scale 
bar represents 5 µm (a), 1 µm (b). 
 
Fig. 26. Immunoelectron microscopy and biochemical analysis of brain extracts from 
α-syn injected mice  
Immunoelectron microscopy of sarkosyl-insoluble fraction extracted from mice injected with 
sonicated α-syn fibrils (a). Anti-mouse α-syn-positive (upper), anti-α-syn-positive (syn 
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131-140, middle) and anti-phosphorylated α-syn-positive (PSer129, lower) fibrous structures 
labeled with gold particles were observed. The scale bar represents 200 nm. Immunoblot 
analysis of sarkosyl-insoluble fractions and sarkosyl-soluble fractions from injected mice. 
sarkosyl-insoluble fractions were sonicated or none. Phosphorylated α-syn was detected with 
anti-phosphorylated α-syn PSer129 antibody. α-Syn was detected with anti-syn 131-140 
antibody. Tubulin-α was used as the loading control.  
 
Fig. 27. Immunoblot analysis of cells treated with brain extracts from α-syn injected mice  
Sarkosyl-insoluble fraction with sonication or without sonication, extracted from mice injected 
with monomer α-syn and α-syn fibrils, was introduced into SH-SY5Y cells overexpressing 
human α-syn. Immunoblot analysis of sarkosyl-insoluble fractions (ppt) and sarkosyl-soluble 
fractions  extracted from cells transfected with mock , sarkosyl-insoluble fraction without 
sonication or with sonication from monomer α-syn-injected mouse and sarkosyl-insoluble 
fraction without sonication or with sonication from α-syn fibril-injected mouse are shown (a). 
Phosphorylated α-syn was detected with anti-phosphorylated α-syn PSer129 antibody. α-Syn 
was detected with anti-syn 131-140 antibody. Tubulin-α was used as the loading control. 
Quantification of PSer129-positive sarkosyl-insoluble fractions shown in Fig. 26 (a) (b). The 
results are expressed as means ± SEM. (n=3). *P < 0.05 by Student’s t-test against the value of 
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control (mock). #P < 0.05 by Student’s t-test against the value of control (mock). A.U., arbitrary 
unit. 
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